Widely used:Recently Viewed
Clear All
$26,460 Mln
--
7.29
--
0.06
-15.17 %
--
--
--
-5082575
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
BeiGene (BGNE)
| 36.42 | 30.69 | 66.27 | 41.21 | -11.65 | 15.22 | -- |
|
BSE Sensex
| 13.08 | -1.05 | 2.13 | 24.69 | 11.60 | 16.47 | 11.89 |
|
S&P Midcap 400
| 12.11 | 3.53 | 6.90 | 28.41 | 5.13 | 10.60 | 8.62 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|
|---|---|---|---|---|---|---|---|
|
BeiGene (BGNE)
| -18.00 | -18.82 | 4.85 | 55.88 | 18.18 | 43.25 | 221.87 |
|
S&P Midcap 400
| 14.45 | -14.48 | 23.21 | 11.81 | 24.05 | -12.43 | 14.45 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 | 27.91 |
|
Stock
|
Peer Median
|
||
|---|---|---|---|
loading... |
|||
|
Stock
|
Peer Median
|
||
|---|---|---|---|
loading... |
|||
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Our rating system has guided millions of investors in the past 20 years.
$26,460.14 Mln
$3,096.54 Mln
$215.41 Mln
$2,615.81 Mln
$1,089.98 Mln
High
$126.97 - 248.16
97,226,000
NASDAQ: BGNE
Camana Bay
https://www.beigene.com
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. Its commercial stage products include BRUKINSA, a small molecule inhibitor of... Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. The company's clinical stage products comprise BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; BGB-10188; BGB-21447, a Bcl-2 inhibitor; Ociperlimab (BGB-A1217), a TIGIT inhibitor; Zanidatamab, a bispecific HER2-targeted antibody; Surzebiclimab (BGB-A425), a TIM-3 inhibitor; BGB-A445, an OX40 agonist antibody; BGB-15025, a small molecule inhibitor of HPK1; BGB-24714, a SMAC mimetic; BGB-26808, a HPK-1 inhibitor; Lifirafenib and BGB-3245 that are inhibitors of RAF; BGB-30813; BGB-A3055, an anti-CCR8 antibody; and BGB-43395, a CDK-4 inhibitor. It also has various preclinical programs. The company has license agreements with Ensem Therapeutics, Inc.; Shandong Luye Pharmaceutical Co., Ltd.; Shoreline Biosciences, Inc.; Nanjing Leads Biolabs, Inc.; EUSA Pharma; Assembly Biosciences, Inc.; Bio-Thera Solutions, Ltd.; Amgen Inc.; and Beijing Novartis Pharma Co., Ltd. BeiGene, Ltd. was incorporated in 2010 and is based in Camana Bay, the Cayman Islands. Address: 94 Solaris Avenue, Camana Bay, Cayman Islands, KY1-1108 Read more
The total asset value of BeiGene Ltd (BGNE) stood at $ 7,651 Mln as on 30-Jun-24
The share price of BeiGene Ltd (BGNE) is $246.04 (NASDAQ) as of 04-Oct-2024 16:00 EDT. BeiGene Ltd (BGNE) has given a return of -11.65% in the last 3 years.
BeiGene Ltd (BGNE) has a market capitalisation of $ 26,460 Mln as on 02-Oct-2024. As per Value Research classification, it is a Mid Cap company.
The P/B ratio of BeiGene Ltd (BGNE) is 7.29 times as on 02-Oct-2024, a 187% premium to its peers’ median range of 2.54 times.
Since, TTM earnings of BeiGene Ltd (BGNE) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the BeiGene Ltd (BGNE) and enter the required number of quantities and click on buy to purchase the shares of BeiGene Ltd (BGNE).
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. Its commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. The company's clinical stage products comprise BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; BGB-10188; BGB-21447, a Bcl-2 inhibitor; Ociperlimab (BGB-A1217), a TIGIT inhibitor; Zanidatamab, a bispecific HER2-targeted antibody; Surzebiclimab (BGB-A425), a TIM-3 inhibitor; BGB-A445, an OX40 agonist antibody; BGB-15025, a small molecule inhibitor of HPK1; BGB-24714, a SMAC mimetic; BGB-26808, a HPK-1 inhibitor; Lifirafenib and BGB-3245 that are inhibitors of RAF; BGB-30813; BGB-A3055, an anti-CCR8 antibody; and BGB-43395, a CDK-4 inhibitor. It also has various preclinical programs. The company has license agreements with Ensem Therapeutics, Inc.; Shandong Luye Pharmaceutical Co., Ltd.; Shoreline Biosciences, Inc.; Nanjing Leads Biolabs, Inc.; EUSA Pharma; Assembly Biosciences, Inc.; Bio-Thera Solutions, Ltd.; Amgen Inc.; and Beijing Novartis Pharma Co., Ltd. BeiGene, Ltd. was incorporated in 2010 and is based in Camana Bay, the Cayman Islands. Address: 94 Solaris Avenue, Camana Bay, Cayman Islands, KY1-1108
The CEO & director of Mr. John V. Oyler. is BeiGene Ltd (BGNE), and CFO & Sr. VP is Mr. John V. Oyler.
There is no promoter pledging in BeiGene Ltd (BGNE).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
110
|
|
|
85
|
|
|
58
|
|
|
46
|
| BeiGene Ltd. (BGNE) | Ratios |
|---|---|
|
Return on equity(%)
|
-15.17
|
|
Operating margin(%)
|
-30.13
|
|
Net Margin(%)
|
-16.91
|
|
Dividend yield(%)
|
--
|
Yes, TTM profit after tax of BeiGene Ltd (BGNE) was $215 Mln.
$12.40
